Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Aducanumab Therapy to Treat Alzheimer’s Disease: A Narrative Review
Semira Abdi Beshir, Aadith Soorya, Affana Parveen, et al.
International Journal of Alzheimer s Disease (2022) Vol. 2022, pp. 1-10
Open Access | Times Cited: 83

Showing 26-50 of 83 citing articles:

Imaging Methods Applicable in the Diagnostics of Alzheimer’s Disease, Considering the Involvement of Insulin Resistance
Petra Hnilicová, Ema Kantorová, Stanislav Šutovský, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3325-3325
Open Access | Times Cited: 10
Developing Non-Invasive Molecular Markers for Early Risk Assessment of Alzheimer's Disease
Tapas Kumar Sur, Tanmoy Mondal, Zarish Noreen, et al.
Biomarkers in Neuropsychiatry (2025), pp. 100120-100120
Open Access
Revolutionizing cancer treatment: The power of dendritic cell-based vaccines in immunotherapy
Mohsen Sheykhhasan, Amirhossein Ahmadieh-Yazdi, Reza Heidari, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 184, pp. 117858-117858
Closed Access
Combining GWAS Summary Data and Proteomics Identified Potential Drug Targets in Dementia
Yingjie Zhao, Fei Lu, Yongtao Duan
Molecular Neurobiology (2025)
Closed Access
Monoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics
Michael Rosenbloom, Andrea Schnee, Saanvi Nimma, et al.
Journal of Neurology (2025) Vol. 272, Iss. 6
Closed Access
Intermittent treatment with Apremilast, a phosphodiesterase-4 inhibitor, ameliorates Alzheimer's-like pathology and symptoms through multiple targeting actions in aged T2D rats
Adel A. Gomaa, Hanan S.M. Farghaly, Asmaa M. Ahmed, et al.
International Immunopharmacology (2023) Vol. 117, pp. 109927-109927
Closed Access | Times Cited: 9
The human neurosecretome: extracellular vesicles and particles (EVPs) of the brain for intercellular communication, therapy, and liquid-biopsy applications
Taliah Soleymani, Tzu-Yi Chen, Edgar Gonzalez‐Kozlova, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 9
Loss of Direct Vascular Contact to Astrocytes in the Hippocampus as an Initial Event in Alzheimer’s Disease. Evidence from Patients, In Vivo and In Vitro Experimental Models
Carlos Pomilio, José Presa, Camila Oses, et al.
Molecular Neurobiology (2024) Vol. 61, Iss. 8, pp. 5142-5160
Closed Access | Times Cited: 3
Current trends and updates in the treatment of Alzheimer's disease
Nisha I. Parikh, Palak K. Parikh, Hetansh J. Rao, et al.
Elsevier eBooks (2024), pp. 373-390
Closed Access | Times Cited: 3
Treatment with Blackberry Extract and Metformin in Sporadic Alzheimer’s Disease Model: Impact on Memory, Inflammation, Redox Status, Phosphorylated Tau Protein and Insulin Signaling
Júlia Eisenhardt de Mello, Fernanda Cardoso Teixeira, Alessandra dos Santos, et al.
Molecular Neurobiology (2024) Vol. 61, Iss. 10, pp. 7814-7829
Closed Access | Times Cited: 3
Navitoclax safety, tolerability, and effect on biomarkers of senescence and neurodegeneration in aged nonhuman primates
Edward F. Greenberg, Martin J. Voorbach, Alexandra Smith, et al.
Heliyon (2024) Vol. 10, Iss. 16, pp. e36483-e36483
Open Access | Times Cited: 3
Alzheimer’s Disease Immunotherapy and Mimetic Peptide Design for Drug Development: Mutation Screening, Molecular Dynamics, and a Quantum Biochemistry Approach Focusing on Aducanumab::Aβ2–7 Binding Affinity
Victor L. B. França, Eveline M. Bezerra, Roner F. da Costa, et al.
ACS Chemical Neuroscience (2024)
Open Access | Times Cited: 3
Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer’s disease
Ibtisam Mumtaz, Mir Owais Ayaz, Mohamad Sultan Khan, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 13
MRI and Clinical Biomarkers Overlap between Glaucoma and Alzheimer’s Disease
Alessio Martucci, Francesca Di Giuliano, Silvia Minosse, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14932-14932
Open Access | Times Cited: 8
Taxifolin for Cognitive Preservation in Patients with Mild Cognitive Impairment or Mild Dementia
Yorito Hattori, Satoshi Saitô, Yuriko Nakaoku, et al.
Journal of Alzheimer s Disease (2023) Vol. 93, Iss. 2, pp. 743-754
Open Access | Times Cited: 7
Developing theragnostics for Alzheimer's disease: Insights from cancer treatment
Hyunju Lee, Hee-Jeong Choi, Yoo Joo Jeong, et al.
International Journal of Biological Macromolecules (2024) Vol. 269, pp. 131925-131925
Open Access | Times Cited: 2
Advances in Understanding and Managing Alzheimer's Disease: From Pathophysiology to Innovative Therapeutic Strategies
Sunny Rathee, D. Sen, Vishal Pandey, et al.
Current Drug Targets (2024) Vol. 25, Iss. 11, pp. 752-774
Closed Access | Times Cited: 2
Aducanumab: una mirada dos años después de su aprobación
Astrid Torres, Loida Camargo, Norman López
Biomédica (2024) Vol. 44, Iss. Sp. 1, pp. 42-46
Open Access | Times Cited: 2
Immunotherapy in Alzheimer’s Disease: Current Status and Future Directions
Kshitij Vashisth, Shivani Sharma, Shampa Ghosh, et al.
Journal of Alzheimer s Disease (2024) Vol. 101, Iss. s1, pp. S23-S39
Closed Access | Times Cited: 2
The role of the FKBP51-Hsp90 complex in Alzheimer’s Disease: An emerging new drug target
Xavier Jeanne, Zsolt Török, László Vı́gh, et al.
Cell Stress and Chaperones (2024)
Open Access | Times Cited: 2
Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases
Cencan Xing, Hongyu Chen, Wangyu Bi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13446-13446
Open Access | Times Cited: 2
Recent Advances in the Search for Effective Anti-Alzheimer’s Drugs
Martyna Ogos, Dorota Stary, Marek Bajda
International Journal of Molecular Sciences (2024) Vol. 26, Iss. 1, pp. 157-157
Open Access | Times Cited: 2
Many faces and functions of GSKIP: a temporospatial regulation view
Nian-Siou Wu, Yifan Lin, Inhou Chu, et al.
Cellular Signalling (2022) Vol. 97, pp. 110391-110391
Closed Access | Times Cited: 9
The Fate of Tau Aggregates Between Clearance and Transmission
Assel Seitkazina, Kyu Hyeon Kim, Erin Fagan, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 8
Identification of Uncaria rhynchophylla in the Potential Treatment of Alzheimer’s Disease by Integrating Virtual Screening and In Vitro Validation
Shuang Jiang, Gilwa Borjigin, Jiahui Sun, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15457-15457
Open Access | Times Cited: 4

Scroll to top